Yin wasanni da kuma amfani da su zuwa abubuwan da suka shafi rayuwarmu da kuma ayyuka, wani abin da ake kira "gamification," yana cigaba da sauri ta hanyar gudunmawa ta hanyar duniyarmu. Kayan da ya dace ya yi ta hanyoyi daban-daban ciki har da wasanni masu kyau, wasanni don ƙarfafa sauye-sauyen salon rayuwa, har ma da wasanni don ƙara haɓaka don kammala ayyukan aiki.
Genentech, babban kamfanin kamfanonin biopharmaceutical, yanzu yana haɗar kimiyyar bayan maganin ciwon daji-kuma ba su kadai ba ne. Amma ta yaya gamuwa ya dace da marasa lafiya na ciwon daji? To, ga mai haƙuri da ciwon daji, ƙoƙarin shirya shirin nan gaba zai iya zama mummunar. Harshen kimiyya, fasahar fasaha, raguwa, da acronyms ba su taimaka wa batutuwa ba. Alal misali, ana iya auna lokutan tsira, alal misali, ƙwayar cutar ta kamu da ciwon daji. A nan ne Ofishin Jakadancin: MRD ya dace.
Ofishin Jakadancin: MRD
Genentech ya kirkiro sabon saiti na 60, Wurin Jakadancin: MRD, don koya wa mutane game da cutar marasa lafiya kadan (MRD) - hanya ce ta aunawa ga mutumin da ya mayar da martani ga maganin ciwon daji wanda aka ba shi.
Yawancin ciwon daji na jini da ya haɗa da cutar sankarar bargo na jini (CLL), cutar sankarar mafi girma na al'ada - iri ne da ake buƙatar sarrafawa tare da maganin cututtukan ciwon daji a tsawon lokaci, ma'ana ba za ka iya kawar da kowane kwayar cutar ciwon daji ba.
Wannan yana haifar da sake komawa, don haka likitoci suyi ƙoƙari su yi hankali idan yazo da kalmar "warkewarta."
A Ofishin Jakadancin: MRD, mai amfani yana tafiya cikin jini, yana lalata yawancin ciwon kanji yadda zasu iya tare da manufar kai MRD-negativity. Yana da mahimmanci a lura cewa wannan wasa shine na farko don nishaɗi kuma ba nufin nufin lafiya ba ko cikakkiyar ilimin kimiyya, amma don ƙaddamar da ƙwarewar halin MRD.
MRD-Negativity
Lokacin da wanda ke tare da CLL ya kai MRD-negativity, yana nufin cewa babu wani kwayar cutar ciwon daji da za'a iya ganowa a cikin jini ko ƙananan samfurori ta amfani da gwaje-gwajen musamman. Yanzu, don ciwon daji kamar CLL, har yanzu ana iya yiwuwa cutar ta dawo, ko da bayan mai haƙuri ya kai MRD-negativity; duk da haka, cimma MRD-negativity shakka alama ya zama mai kyau abu kuma a nan shi ne dalilin da ya sa:
- Akwai hanyoyi da dama don auna cutar nauyi a ciwon daji. Matsayin MRD-korau a CLL yana yiwuwa tare da fasahar sababbin fasaha.
- Lokacin da wanda ke tare da CLL ya kai MRD-negativity, yana nufin babu wani ciwon daji da za'a iya ganowa a cikin jini ko ƙananan samfuran samfurori ta yin amfani da takamaiman gwaje-gwajen da ke amfani da hanyoyin da suka fi dacewa fiye da hanyoyin tsofaffin kwayoyi da 100 a ƙarƙashin microscope.
- MRD-negativity na iya haɗawa da sakamako mafi kyau. Dole ne ayi aiki da yawa amma shaidun shaida masu girma suna nuna cewa MRD-negativity bayan wasu jiyya na iya hango tsinkayar gafarar da ya fi tsayi kuma zai yiwu sau da yawa rayuwa sau da yawa ga cutar jini.
Canje-canje na Cancer na Future
Wasu shirye-shiryen da aka shirya da kuma hotuna daban-daban da kuma cikakkun bayanai suna samuwa a kan shafin yanar gizon Genentech don taimaka maka ka fahimci tsarin ciwon rigakafi na ciwon daji - hanyar da ke haifar da ci gaba da kare lafiyar kwayoyin cutar kanjamau.
Sources:
Smolej L, Šimkovič M. M hanya mai kyau don kula da cutar cutar sankarar lymphocytic na kullum. Tarihin Kimiyya Kimiyya: AMS. 2016; 12 (2): 448-456.
Hallek M, Cheson BD, Catovsky D, et al. Sharuɗɗa don ganewar asali da kuma maganin cutar cutar sankarar lymphocytic na kullum: rahoto daga Cibiyar Nazarin Kasashen Duniya a kan Likar cutar sankarar Lymphocytic na yau da kullum da ke sabunta ka'idojin Cibiyar Ƙungiyar Ciwon Cancer ta kasa ta 1996. Jinin jini . 2008; 111: 5446-56.
Hallek M, Fischer K, Fingerle-Rowson G, et al. Ƙarar rituximab zuwa fludarabine da cyclophosphamide a marasa lafiya da cutar cutar sankarar lymphocytic na kullum: wani ƙaddamarwa, bude-lakabi, gwajin lokaci 3. Lancet. 2010; 376: 1164-74.
Botter S, Ritgen M, Fischer K, et al. Mahimmancin ƙwayoyin cutar ƙayyadaddun kwayar halitta shine mai hangen nesa na rashin cigaba da kuma ci gaba da rayuwa a cikin cutar cutar sankarar lymphocytic na kullum: bincike mai yawa daga binciken GCLLSG CLL8 bazuwar. J Jara Incol . 2012; 30: 980-8.